StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.0
  1. Startseite
  2. /Verbindung

Lactulose

HCID 11333
Neue NotizNeue ReaktionAnfrage stellen
Druckvorschau
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
4618-18-2
Standard-SMILES
OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
InChIKey
JCQLYHFGKNRPGE-FCVZTGTOSA-N
Summenformel
C12H22O11
Durchschnittliche Molmasse
342,3 g/mol
Monoisotopische Masse
342,11621151

Überblick

Lactulose is a synthetic galactosylfructose disaccharide used in the treatment of constipation and hepatic encephalopathy. It has a role as a laxative and a gastrointestinal drug.

Namen und Bezeichner

Bevorzugter Name
Lactulose
IUPAC
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
Lokaler Name
Lactulose
Englischer Name
Lactulose
Summenformel
C12H22O11
Molmasse
342.3

Namen und Synonyme

lactuloseD-LactuloseBifiteralCephulacChronulacConstilacLactulosaAcilacCholac4618-18-2ConstuloseLactulosum
Weitere Namen anzeigen
Lactulose Concentrateruguotang[UL-13C12]lactulose4-O-hexopyranosylhex-2-ulofuranoseLactulose for peak identification CRS(3S,4R,5R)-1,3,5,6-tetrahydroxy-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxyMethyl)tetrahydro-2H-pyran-2-yl)oxy)hexan-2-one
EnuloseGenerlacHeptalacLaxilosePortalacKristaloseLattulosioDTXSID5045833

Datenbank-Bezeichner

CAS
4618-18-2、58166-24-8、58166-25-9
PubChem CID
11333
DTXSID
DTXSID5045833

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-4,3
Polarare Oberfläche (TPSA)
190 Ų
H-Brücken-Donoren
8
H-Brücken-Akzeptoren
11
Frei drehbare Bindungen
5
Schwere Atome
23
Formalladung
0
Komplexität
395

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Cosmetics · 2 Einträge

Cosmetic ingredients (Lactulose) -> CIR (Cosmetic Ingredient Review)

Humectant; Skin conditioning

LogP-4.3
Solubility · 2 Einträge

Soluble in cold water, hot water. Solubility in water: 76.4% @ 30 deg. C

764.0 mg/mL

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Gastrointestinal Agents; Laxatives

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Medicines for other common symptoms in palliative care

Melting Point169 °C
Physical DescriptionSolid
Collision Cross Section · 4 Einträge

171.3 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

180.1 Ų [M+Na]+ [CCS Type: DT; Method: stepped-field]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 3 Einträge

This chemical does not meet GHS hazard criteria for 100% (9 of 9) of all reports.

Not Classified

Aggregated GHS information provided per 9 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory InformationLactulose: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesNot Classified

Toxikologische Informationen

Adverse Effects · 1 Eintrag

Because lactulose has insignificant absorption by the gut and undergoes rapid excretion by the kidneys, its effects remain localized to the gut microenvironment. Side effects would include increased bowel sounds (borborygmi), increased flatus, and a sensation of bloating. Since lactulose's intended use is to soften the stool quantity and increase the stool amount, its most significant side effect remains diarrhea. The diarrhea is dose-dependent and decreases in severity with a reduction in the dose of lactulose.

Toxicity Summary · 2 Einträge

Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org

Clinically, documentation on lactulose toxicity is lacking. Specific studies using rats inoculated with various concentrations of lactulose syrup ranging from 0.5% to 5% revealed no evidence of toxicity. However, there have been study results indicating the ability of lactulose to induce lithium toxicity in psychiatric patients. This effect is more broadly attributable to lactulose's ability to induce dehydration through its osmotic action, depletion of total body volume, and the resultant poor renal excretion of lithium. Although rare, documented allergic reactions to lactulose have been recorded in patients with milk allergies.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

A06AD11

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

A06AD11

Protein BindingNegligible amounts of lactulose - metabolized or non-metabolized - are absorbed into the body.. Regardless, data regarding the protein binding of lactulose is not readily available or accessible.
Pharmacodynamics · 1 Eintrag

Lactulose formulations are most commonly administered via the oral route or the rectal route. Consequently, because the substance experiences minimal absorption by the gut it typically remains localized in the gastrointestinal tract environment and ultimately demonstrates almost all of its pharmacologic effects within the gut. In particular, as lactulose elicits its laxative effects in enhancing stool amounts and softening stool, such biochemical and physiologic activities can cause increased bowel sounds (borborygmi), a feeling of bloatedness, belching, frequent flatus, and diarrhea.

Mechanism of Action · 1 Eintrag

Lactulose is a synthetic disaccharide derivative of lactose that consists of one molecule of galactose and one molecule of fructose. Saccharolytic bacteria present in the large intestine subsequently break the substance down into organic acids like lactic acid and small amounts of formic and acetic acids. Such resultant volatile fatty acid metabolites, in combination with hydrogen and methane that is also generated consequently enhance intraluminal gas formation, peristaltic gut motility, and elicit an osmotic effect that facilitates an increase in the water content of stool as well as associated stool softening. All of these actions ultimately assist in facilitating and increasing the frequency of bowel movements in patients experiencing constipation, although it may take 24 to 48 hours after using the medication for this laxative effect to become evident. At the same time, the formation of such acids via the metabolism of lactulose by colonic bacteria also acidifies the contents of the colon, thereby contributing to the treatment of portal-systemic encephalopathy (PSE). As one of the principal features of PSE involves the accumulation of nitrogenous waste products like ammonia in the systemic circulation, a state in which the colonic contents become more acidic than blood allows ammonia in the circulation to diffuse into the colon.. Furthermore, ammonia that diffuses into the acidic colon is ionized to ammonium ions that are incapable of being absorbed back into the blood. These effects, combined with the laxative action of lactulose facilitates the excretion of excess ammonia. And finally, it is also believed that an acidic colonic environment results in the elimination of urease-producing bacteria that contribute to the formation of ammonia while surviving colonic bacteria use up any trapped ammonia in the colon as a source of nitrogen for protein synthesis.

Zugehörige Reaktionen

9
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1726
HRID 1726als Produktuspto-grants-1998_03
Reaktionsgleichung von HRID 1727
HRID 1727als Eduktuspto-grants-1998_03
Reaktionsgleichung von HRID 215682
HRID 215682als Eduktuspto-grants-2012_06
Reaktionsgleichung von HRID 324923
HRID 324923als Produktuspto-grants-2001_04
Reaktionsgleichung von HRID 485636
HRID 485636als Eduktuspto-grants-1985_08
Reaktionsgleichung von HRID 1076820
HRID 1076820als Eduktuspto-grants-1976_05
Reaktionsgleichung von HRID 1086962
HRID 1086962als Produktuspto-grants-1991_07
Reaktionsgleichung von HRID 1174429
HRID 1174429als Eduktuspto-grants-2010_11
Seite 1 von 2

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Weitere Aktionen
Neue NotizNeue ReaktionAnfrage stellen
ChEMBL
CHEMBL296306
ChEBI
CHEBI:6359
UNII
9XH2P2N8EP
EC Number
225-027-7
Nikkaji
J3.412F

169.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

179 Ų [M+Na]+

Physikochemische Eigenschaften

Schmelzpunkt
169 °C · ~169 °C (dec.)
Siedepunkt
397.76 °C · 397.76°C (rough estimate)
Dichte
1 · 1,32g/cm
Brechungsindex
1 · 1,45-1,47
storage temp.
Refrigerator
Löslichkeit
Freely soluble in water, sparingly soluble in methanol, practically insoluble in toluene.
Aggregatzustand
Powder
pka
11.67 · 11.67±0.20(Predicted)
Farbe
White to almost white
Wasserlöslichkeit
76.4 G/100 · 76.4 G/100 ML (30 ºC)
Merck
5346 · 5346
BRN
93773 · 93773
BCS Class
2 · 2
Kosmetik-Inhaltsstoffe Funktionen
HUMECTANTSKIN CONDITIONING
InChI
1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12+/m1/s1
InChIKey
PFCRQPBOOFTZGQ-VZXVHDRGSA-N
SMILES
OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
LogP
-2.885 · -2.885 (est)
CAS Datenbank
4618 · 4618-18-2(CAS DataBase Reference)
EPA chemische Informationen
4 · D-Fructose, 4-O-.beta.-D-galactopyranosyl- (4618-18-2)
CAS Number Unlabeled
4618 · 4618-18-2
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Lactulose

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
2
tsca
TSCA listed
hs_code
29400090
RTECS-Nr.
LS6965000
safety_code
24/25
Speicherklasse
11 - Combustible Solids
Biological Half-LifeThe data regarding the half-life of lactulose is not readily available or accessible.
Metabolism/Metabolites · 1 Eintrag

Lactulose is essentially only metabolized in the colon by saccharolytic bacteria that are present there. In particular, the substance is broken down into lactic acid and small amounts of acetic and formic acid. Specific examples of bacteria that normally inhabit the large intestine that are capable of lactulose metabolism include Lactobacilli, Bacteroides, Escherichia coli, and Clostridia.

FDA Pharmacological Classification · 6 Einträge

9U7D5QH5AE

LACTULOSE

Established Pharmacologic Class [EPC] - Osmotic Laxative

Mechanisms of Action [MoA] - Osmotic Activity

Mechanisms of Action [MoA] - Acidifying Activity

Physiologic Effects [PE] - Stimulation Large Intestine Fluid/Electrolyte Secretion

MeSH Pharmacological ClassificationDrugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Absorption, Distribution and Excretion · 4 Einträge

After administration by the oral route, less than 3% of the given dose of lactulose solution is absorbed by the small intestine. The remaining unabsorbed lactulose reaches the large intestine where it is metabolized - but even then, negligible quantities of unchanged lactulose or its metabolites are absorbed across the colon.

The renal excretion of any lactulose that manages to be absorbed into the circulation has been determined to be 3% or less and is generally complete within 24 hours. Any unabsorbed lactulose is largely excreted with stool.

Negligible amounts of lactulose - metabolized or non-metabolized - are absorbed into the body.. Most lactulose that is administered subsequently remains predominantly around the gastrointestinal tract area.

Negligible amounts of lactulose - metabolized or non-metabolized - are absorbed into the body.. Regardless, data regarding the clearance of lactulose is not readily available or accessible.

Tissue LocationsIntestine
Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesCIR ingredient: Lactulose
Use ClassificationCosmetics -> Humectant; Skin conditioning

Anwendungen

VerwendenLactulose is is a synthetic, non-digestible sugar used in the treatment of chronic constipation; laxative.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

beta-D-FructopyranoseLactoseD-Galactose 1-[2-(2-azidoethoxy)ethoxyethyl]-2,3,4,6-tetra-O-acetateAluminiumnatriumoxidFructose

Ergänzende Hinweise

DefinitionChEBI: A synthetic galactosylfructose disaccharide used in the treatment of constipation and hepatic encephalopathy.